drugset
drugset / Trial / NCT01431807

Long-term Study of SYR-472

NCT01431807 ↗

Phase 3 Completed 680 enrolled Takeda
NaSingle-groupOpen-labelTreatment

Summary

To evaluate the safety and efficacy of long-term treatment with SYR-472 in diabetic patients.

Timeline

Start
2011-09-01
Primary completion
2013-06-01
Completion
2013-06-01

Drugs

EvaluationDrugModalityDoseRoute
Subject Trelagliptin Small molecule — Oral

Indications

diabetes mellitus